Romosozumab (Evenity) for Postmenopausal Osteoporosis

被引：0
|
作者：
不详
机构：
来源：
MEDICAL LETTER ON DRUGS AND THERAPEUTICS | 2019年 / 61卷 / 1573期
关键词：
WOMEN;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：83 / 86
页数：4
相关论文
共 50 条
  • [21] Cost effectiveness of romosozumab versus teriparatide for severe postmenopausal osteoporosis in Japan
    Hagino, H.
    Tanaka, K.
    Silverman, S.
    McClung, M.
    Gandra, S. R.
    Charokopou, M.
    Adachi, K.
    Johnson, B.
    Stollenwerk, B.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2021, 32 (10) : 2011 - 2021
  • [22] Romosozumab for osteoporosis
    Cosman F
    Crittenden DB
    Adachi JD
    [J]. 中华物理医学与康复杂志, 2016, 38 (12) : 915 - 915
  • [23] Romosozumab: A Review in Postmenopausal Osteoporosis (vol 37, pg 845, 2020)
    Paik, Julia
    Scott, Lesley J.
    [J]. DRUGS & AGING, 2020, 37 (11) : 857 - 858
  • [24] Cost effectiveness of romosozumab versus teriparatide for severe postmenopausal osteoporosis in Japan
    H. Hagino
    K. Tanaka
    S. Silverman
    M. McClung
    S. R. Gandra
    M. Charokopou
    K. Adachi
    B. Johnson
    B. Stollenwerk
    [J]. Osteoporosis International, 2021, 32 : 2011 - 2021
  • [25] Romosozumab added to ongoing denosumab in postmenopausal osteoporosis, a prospective observational study
    Adami, Giovanni
    Pedrollo, Elisa
    Rossini, Maurizio
    Fassio, Angelo
    Braga, Vania
    Pasetto, Emma
    Pollastri, Francesco
    Benini, Camilla
    Viapiana, Ombretta
    Gatti, Davide
    [J]. JBMR PLUS, 2024, 8 (04)
  • [26] Effects of prior osteoporosis treatment on the treatment response of romosozumab followed by denosumab in patients with postmenopausal osteoporosis
    K. Ebina
    Y. Etani
    H. Tsuboi
    Y. Nagayama
    M. Kashii
    A. Miyama
    Y. Kunugiza
    M. Hirao
    G. Okamura
    T. Noguchi
    K. Takami
    A. Goshima
    T. Miura
    Y. Fukuda
    T. Kurihara
    S. Okada
    K. Nakata
    [J]. Osteoporosis International, 2022, 33 : 1807 - 1813
  • [27] Effects of prior osteoporosis treatment on the treatment response of romosozumab followed by denosumab in patients with postmenopausal osteoporosis
    Ebina, K.
    Etani, Y.
    Tsuboi, H.
    Nagayama, Y.
    Kashii, M.
    Miyama, A.
    Kunugiza, Y.
    Hirao, M.
    Okamura, G.
    Noguchi, T.
    Takami, K.
    Goshima, A.
    Miura, T.
    Fukuda, Y.
    Kurihara, T.
    Okada, S.
    Nakata, K.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2022, 33 (08) : 1807 - 1813
  • [28] A systematic review and meta-analysis of efficacy and safety of Romosozumab in postmenopausal osteoporosis
    S. Singh
    S. Dutta
    S. Khasbage
    T. Kumar
    J. Sachin
    J. Sharma
    S B Varthya
    [J]. Osteoporosis International, 2022, 33 : 1 - 12
  • [29] A systematic review and meta-analysis of efficacy and safety of Romosozumab in postmenopausal osteoporosis
    Singh, S.
    Dutta, S.
    Khasbage, S.
    Kumar, T.
    Sachin, J.
    Sharma, J.
    Varthya, S. B.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2022, 33 (01) : 1 - 12
  • [30] Romosozumab is associated with greater trabecular score improvement compared to denosumab in postmenopausal osteoporosis
    Shin, Sungjae
    Rhee, Yumie
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2023, 38 : 166 - 166
12345